Using micro data on virtually all of the drugs and diseases of over 500,000 people enrolled in Puerto Rico's Medicaid program, we examine the impact of the vintage (original FDA approval year) of drugs used to treat a patient on the patient's 3-year probability of survival, controlling for demographic characteristics (age, sex, and region), utilization of medical services, and the nature and complexity of illness. We find that people using newer drugs during January-June 2000 were less likely to die by the end of 2002, conditional on the covariates. The estimated mortality rates are strictly declining with respect to drug vintage. For pre-1970 drugs, the estimated mortality rate is 4.4%. The mortality rates for 1970s, 1980s, and 1990s drugs are 3.6%, 3.0%, and 2.5%, respectively.
Clinical studies of specific new drugs have shown that these drugs increase survival rates. Here are three examples:
• Stenestrand et al (2001) studied the impact on survival of statin treatment following acute myocardial infarction. They found that 1-year mortality was 9.3% in the no-statin group and 4.0% in the statin treatment group. • Grier et al (2003) found that adding two experimental drugs to the standard fourdrug chemotherapy regimen has significantly improved survival in patients with non-metastatic Ewing's sarcoma, a highly malignant bone cancer of children and young adults. The overall survival rate increased from 61 percent to 72 percent for Ewing's sarcoma patients with localized disease who underwent the experimental six-drug chemotherapy. • The journal U.S. Pharmacist (2002) reported that patients suffering from advanced metastatic melanoma who were treated with a combination of an investigational agent, Ceplene, and interleukin-2 (IL-2) had twice the survival rate as patients who were treated with IL-2 only. The patients were enrolled in a threeyear study. The study also showed that the Ceplene/IL-2 combination significantly increased survival in a subpopulation group of advanced metastatic melanoma patients with liver metastases. The rate of survival in this group was six times that of the group given IL-2 only.
Also, I have performed several studies using aggregate data (Lichtenberg (2002 (Lichtenberg ( -2004 ) that indicated that the introduction of new drugs has increased longevity. The objective of the present study is to examine the impact of the vintage (original FDA approval year) of drugs used to treat a patient on the patient's probability of survival, using micro data on virtually all drugs and diseases from Puerto Rico's Medicaid program, which covers about 1.5 million people. 1, 2
I. Econometric framework
To determine the effect of the vintage distribution of a person's prescribed medicines on probability of death, conditional on demographic characteristics (age, sex, and region), utilization of medical services, and the nature and complexity of illness, I will estimate the following model: 1 I am grateful to the Puerto Rico Health Insurance Administration (ASES) for providing me access to the data. ASES does not necessarily endorse or accept the conclusions of this study. 2 I hypothesize that survival also depends on the vintage (year of invention or market introduction) of medical products and services other than drugs, such as laboratory tests and radiological and surgical procedures. Unfortunately our ability to measure the vintage of these other products and services is much more limited than out ability to measure the vintage of drugs. I plan to address this issue in future research.
where:
DIED i = 1 if individual i died during the period 2000-2002 = 0 otherwise POST1970 i = the fraction of individual i's prescribed medicines whose active ingredients were approved by the FDA after 1970 POST1980 i = the fraction of individual i's prescribed medicines whose active ingredients were approved by the FDA after 1980 POST1990 i = the fraction of individual i's prescribed medicines whose active ingredients were approved by the FDA after 1990 Z i = a vector of covariates ε i = a disturbance In addition to measuring the shares of diagnoses in each disease category, I calculated the person's "effective number" of diseases. Rather than simply counting the number of disease categories in which a person's diagnoses fell, I computed the following index:
If all of a person's diagnoses fell in one disease category, then N_DISEASE i = 1. If half of a person's diagnoses fell in one disease category, and half fell in a second category, then N_DISEASE i = 2. If 90% of a person's diagnoses fell in one disease category, and 10% fell in a second category, then N_DISEASE i = 1 / (.9 2 + .1 2 ) = 1.22. single-year-of-age-by-sex dummy variables (not shown to conserve space).
Mortality
The coefficients of all three drug-vintage variables are negative and highly significant (p-value < .0001), which is consistent with the hypothesis that ASES beneficiaries using newer drugs during January-June 2000 were less likely to die by the end of 2002, conditional on the covariates. Before considering the implications of the drug-vintage coefficients in detail, we will discuss salient features of the coefficients on the covariates.
The coefficients on all three utilization variables are positive and highly significant: people who used more medical services during January-June 2000 were more likely to die by the end of 2002. For example, one additional medical claim (physician visit) is associated with a .0031 (about 8%) increase in the probability of death. Although utilization of medical services presumably reduces mortality, given initial (pre-treatment) health status, people in the worst initial health utilize the most medical services.
Including the three utilization variables (as well as the diagnosis category and demographic variables) is therefore likely to control for initial health status, which is unobserved and might be correlated with drug vintage (although the sign of the potential correlation is not clear).
The coefficients on the diagnosis category variables indicate differences in mortality rates associated with different diagnoses. They are plotted in Figure 2 . By a large margin, people diagnosed with neoplasms had the highest mortality rate. Diseases 8 Due to the large number of regressors (described below), I estimated a linear probability model, rather than a probit model. 9 The mean of the dependent variable is 3.7%. This is higher than the 3.1% figure reported above, which included ASES beneficiaries with no pharmacy claims.
of the blood and blood-forming organs and diseases of the skin and subcutaneous tissue are two other high-mortality conditions. The lowest-mortality conditions include mental disorders, diseases of the nervous system and sense organs, and diseases of the musculoskeletal system and connective tissue.
The coefficient on N_DISEASE is negative and highly significant, which is somewhat surprising. This indicates that, conditional on the distribution of diagnoses a person had (and other covariates), the greater the effective number of diseases the person had, the lower the probability of death.
The coefficients on the region dummy variables indicate differences in mortality rates associated with different regions. They are plotted in Figure 3 . The mortality rate in Suroeste is almost 1.5 percentage points higher than the mortality rate in the secondhighest region, Este. The regions with the lowest mortality rates are Montana, Guayama, and Arecibo.
Estimates by condition.
In addition to estimating the model using data on the entire population of ASES beneficiaries with pharmaceutical claims, I also estimated the model separately for people with three specific diagnoses: (1) diseases of the circulatory system; (2) endocrine, nutritional and metabolic diseases, and immunity disorders (primarily diabetes); and (3) neoplasms. All three of these conditions exhibit relatively high mortality rates (above 6%), and the first two are highly prevalent (affecting at least one-sixth of the population). There were more than 2600 deaths in each group of people.
Rather than reporting the complete set of estimates (as in Table 1 ) for each group, we report just the coefficients of the three drug-vintage variables, as well as means of key variables for each group, in Table 2 .
The first column of Table 2 shows estimates for the entire population (copied from Table 1 ). The coefficients of the three drug-vintage variables (lines 11, 12, and 13) indicate differences between the mortality rates of people using drugs of different vintages. By combining these coefficients with the average mortality rate (line 3) and the vintage distribution of drugs (lines 7-10), we can infer the (levels of) mortality rates of people using drugs of different vintages. 10
The vintage-specific mortality rates are shown in lines 14-17 of Table 2 and plotted in Figure 4 . The estimated mortality rates are strictly declining with respect to drug vintage. For pre-1970 drugs, the estimated mortality rate is 4.4%. The mortality rates for 1970s, 1980s, and 1990s drugs are 3.6%, 3.0%, and 2.5%, respectively. The differences in mortality rates are highly statistically significant (p-value < .0001).
We can use these estimates to compare the actual mortality rate in the ASES population (resulting from the actual vintage distribution of drugs) to what the mortality rate would have been, given alternative hypothetical vintage distributions of drugs. We consider two such alternative distributions:
• POST1970 = 0%: this would have characterized the distribution of drugs in 1970
• The vintage distribution of U.S. Medicaid Rx's in 2000
The results of these calculations are shown in Figure 5 . To determine these mortality rates, we simply need to solve for k. The overall mortality rate is the weighted average of these mortality rates, weighted by the percentage of people using drugs from each period: 1970-1975 72.2 71.5 1975-1980 73.4 73.3 1980-1985 73.8 74 1985-1990 74.6 74.4 1990-1995 73.9 74.9 1995-2000 74.9 76.2 Source: Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2002 Revision and World Urbanization Prospects: The 2001 Revision, http://esa.un.org/unpp, 25 May 2003 5:45:45 PM. hypothesis that ASES beneficiaries using newer drugs during January-June 2000 were less likely to die by the end of 2002, conditional on the covariates.
IV. Summary
The Puerto Rico Health Insurance Administration (ASES) contracts with private managed care organizations to provide health care services for approximately 1.5 million people, or 40% of the population of Puerto Rico. We examined the impact of the vintage We found that ASES beneficiaries using newer drugs during January-June 2000
were less likely to die by the end of 2002, conditional on the covariates. The estimated mortality rates are strictly declining with respect to drug vintage. For pre-1970 drugs, the estimated mortality rate is 4.4%. The mortality rates for 1970s, 1980s, and 1990s drugs are 3.6%, 3.0%, and 2.5%, respectively. The differences in mortality rates are highly statistically significant (p-value < .0001). In addition to estimating the model for the entire ASES population, we estimated the model separately for three groups: (1) people with diseases of the circulatory system;
(2) people with endocrine, nutritional and metabolic diseases, and immunity disorders (primarily diabetes); and (3) people with neoplasms. With only one exception, within each group the coefficients of all three drug-vintage variables were negative and highly significant.
In this study, we did not control for the effect of the vintage of medical products and services other than drugs on survival, and this may have affected our estimates of the effect of drug vintage. We plan to address this issue in future research. 
